Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Julphar
Healthtrust
Boehringer Ingelheim
McKinsey
US Department of Justice
McKesson
Cantor Fitzgerald
Novartis
Harvard Business School

Generated: October 20, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Inhibitors of Bruton\'s tyrosine kinase
Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Buggy; Joseph J. (Mountain View, CA), Loury; David (Incline Village, NV), Chen; Wei (Fremont, CA)
Assignee: Pharmacylics LLC (Sunnyvale, CA)
Application Number:14/794,685
Patent Claims:1. A method for treating a B-cell proliferative disorder or a mast cell proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (B5): ##STR00127## wherein: Y is a 4-, 5-, 6-membered cycloalkylene ring; each R.sub.a is independently H, halogen, --CF.sub.3, --CN, --NO.sub.2, OH, NH.sub.2, -L.sub.a-(substituted or unsubstituted alkyl), -L.sub.a-(substituted or unsubstituted alkenyl), -L.sub.a-(substituted or unsubstituted heteroaryl), or -L.sub.a-(substituted or unsubstituted aryl), wherein L.sub.a is a bond, O, S, --S(.dbd.O), --S(.dbd.O).sub.2, NH, C(O), CH.sub.2, --NHC(O)O, --NHC(O), or --C(O)NH; G is ##STR00128## R.sub.2 is selected from H, lower alkyl, and substituted lower alkyl; R.sub.6, R.sub.7 and R.sub.8 are independently selected from H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl; and R.sub.12 is H or lower alkyl; or Y and R.sub.12 taken together form a 4-, 5-, or 6-membered heterocyclic ring; or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, further comprising administering to the subject a therapeutically effective amount of an anticancer agent, wherein the compound of Formula (B5) and the anticancer agent are administered simultaneously or sequentially.

3. The method of claim 2, wherein the anticancer agent is an alkylating agent, vinca alkaloid, epipodophyllotoxin, angiogenesis inhibitor, adrenocorticosteroid, progestin, estrogen, antiestrogen, androgen, antiandrogen, or gonadotropin releasing hormone analog, or a combination thereof.

4. The method of claim 2, wherein the anticancer agent is bortezomib, carmustine, carboplatin, cisplatin, cyclophosphamide, chlorambucil, ifosfamide, doxorubicin, vincristine, etoposide, gemcitabine, fludarabine phosphate, fluorouracil, imatinib, geldanamycin, 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), flavopiridol, bortezomib, trastuzumab, methotrexate, melphalan, prednisone, rituximab, dexamethasone, cytarabine, paclitaxel, amrubicin, or azacitidine, or a combination thereof.

5. The method of claim 1, wherein the B cell proliferative disorder or the mast cell proliferative disorder is a mast cell malignancy.

6. The method of claim 1, wherein the B cell proliferative disorder or the mast cell proliferative disorder is a lymphoma.

7. The method of claim 1, wherein the B cell proliferative disorder or the mast cell proliferative disorder is chronic lymphocytic leukemia.

8. The method of claim 1, wherein the B cell proliferative disorder or the mast cell proliferative disorder is diffuse large B-cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, plasma cell myeloma, plasmacytoma, Burkitt's lymphoma/leukemia, or lymphomatoid granulomatosis.

9. The method of claim 1, wherein G is ##STR00129##

10. The method of claim 9, wherein R.sub.6, R.sub.7, and R.sub.8 are H.

11. The method of claim 9, wherein R.sub.7 and R.sub.8 are H; and R.sub.6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

12. The method of claim 11, wherein R.sub.6 is lower alkyl.

13. The method of claim 11, wherein R.sub.6 is substituted lower alkyl.

14. The method of claim 9, wherein R.sub.6 and R.sub.8 are H; and R.sub.7 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

15. The method of claim 14, wherein R.sub.7 is lower alkyl.

16. The method of claim 14, wherein R.sub.7 is substituted lower alkyl.

17. The method of claim 1, wherein G is ##STR00130##

18. The method of claim 17, wherein R.sub.6 is H.

19. The method of claim 17, wherein R.sub.6 is selected from lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl.

20. The method of claim 19, wherein R.sub.6 is lower alkyl.

21. The method of claim 19, wherein R.sub.6 is substituted lower alkyl.

22. The method of claim 1, wherein Y and R.sub.12 taken together form a 6-membered heterocyclic ring.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
RITUXAN
rituximab
VIAL1037050011997-11-26► Subscribe Pharmacylics LLC (Sunnyvale, CA) Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Buggy; Joseph J. (Mountain View, CA), Loury; David (Incline Village, NV), Chen; Wei (Fremont, CA) ► SubscribeRXsearch
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe Pharmacylics LLC (Sunnyvale, CA) Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Buggy; Joseph J. (Mountain View, CA), Loury; David (Incline Village, NV), Chen; Wei (Fremont, CA) ► SubscribeRXOrphansearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
South Africa201007561Sep 26, 2012
South Africa201100893Mar 27, 2013
South Africa201207075Jun 26, 2013
World Intellectual Property Organization (WIPO)2008039218Apr 03, 2008
World Intellectual Property Organization (WIPO)2008039218May 29, 2008
World Intellectual Property Organization (WIPO)2008121742Nov 27, 2008
World Intellectual Property Organization (WIPO)2008121742Oct 09, 2008
United States of America2008076921Mar 27, 2008
United States of America2008108636May 08, 2008
United States of America2008139582Jun 12, 2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Johnson and Johnson
AstraZeneca
Chubb
Deloitte
Cipla
Citi
Federal Trade Commission
Julphar
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot